Vascular Biogenics Ltd. (NASDAQ:VBLT) shares dropped 11.8% on Thursday . The company traded as low as $7.50 and last traded at $7.67. Approximately 724,800 shares changed hands during mid-day trading, an increase of 426% from the average daily volume of 137,716 shares. The stock had previously closed at $8.70.

VBLT has been the topic of a number of research reports. ValuEngine lowered Vascular Biogenics from a “hold” rating to a “sell” rating in a report on Friday, September 8th. Zacks Investment Research lowered Vascular Biogenics from a “hold” rating to a “sell” rating in a report on Friday, August 18th. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Vascular Biogenics in a report on Tuesday, October 3rd. Finally, Chardan Capital raised their price objective on Vascular Biogenics from $20.00 to $25.00 and gave the company a “buy” rating in a report on Monday, November 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $16.00.

Vascular Biogenics (NASDAQ:VBLT) last issued its earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. sell-side analysts forecast that Vascular Biogenics Ltd. will post -0.81 EPS for the current fiscal year.

An institutional investor recently bought a new position in Vascular Biogenics stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Vascular Biogenics Ltd. (NASDAQ:VBLT) in the third quarter, according to its most recent disclosure with the SEC. The firm bought 22,100 shares of the biopharmaceutical company’s stock, valued at approximately $135,000. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.08% of Vascular Biogenics as of its most recent SEC filing. Institutional investors own 8.99% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Vascular Biogenics Ltd. (VBLT) Stock Price Down 11.8%” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/11/16/vascular-biogenics-ltd-vblt-stock-price-down-11-8.html.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Receive News & Stock Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related stocks with our FREE daily email newsletter.